Technical Data Sheet

Purified Mouse anti-PLK1 (pT210)

Product Information

558400		
0.1 mg		
0.5 mg/ml		
K50-483		
Phosphorylated Human PLK1 Peptide		
Mouse IgG1, ĸ		
QC Testing: Human		
Predicted Reactivity: Mouse		
68 kDa		
Aqueous buffered solution containing $\leq 0.09\%$ sodium azide.		

Description

Polo-like kinase (PLK1) is a serine/threonine kinase with structural similarities to Drosophila's Polo kinase and the Cdc5p of Saccharomyces cerevisiae. Like its invertebrate counterparts, PLK1 activity is required for DNA synthesis and is regulated throughout the cell cycle. Furthermore, PLK1 is highly expressed in primary tumors. It associates with the mitotic spindle during mitosis suggesting that, in addition to its role during S phase, PLK1 may play a role during chromosome segregation. This is consistent with its potential role in cancer development. Threonine 210 (T210) is one of the major phoshorylation sites in activated PLK1 obtained from human mitotic cells.

The K50-483 monoclonal antibody recognizes the phosphorylated T210 of human PLK1.



Western blot analysis of PLK1 (pT210) in transformed human epithelioid carcinoma. Lysates from HeLa S3 cell line were probed with purified mouse anti-PLK1 (pT210) monoclonal antibody at concentrations of 0.063, 0.032, and 0.016 µg/ml (Lanes 1, 2, and 3, respectively) with (left panel) or without (right panel) lambda protein phosphatase treatment. PLK1 (pT210) is identified as a band of 68 kDa in the untreated cells.

Preparation and Storage

Store undiluted at 4°C.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Application Notes

Application	
-------------	--

Western blot	Routinely Tested

Latin America/Caribbean

BD Biosciences

bdbiosciences.com							
United States	Canada	Europe	Japan				
877.232.8995	800.979.9408	32.53.720.550	0120.8555.90	1			
For country con	ntact informatio	on, visit bdbiosci	ences.com/conta	ct			

65.6861.0633 55.11.5185.9995

Asia Pacific

Conditions: The information disclosed herein is not to be constructed as a recommendation to use the above product in violation Conditions: The information disclosed herein is not to be constructed as a recommendation to use the above product in violatio of any patents. BD Biosciences will not be help responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is stictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2011 BD



Product Notices

- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before 1. discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not 2 be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
- 3. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.

References

Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004; 279(24):25549-25561. (Biology)

Jang Y-J, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian Polo-like kinase. J Biol Chem. 2002; 277(46):44115-44120. (Biology)

Peter B, Gleixner K, Cerny-Reiterer S, et al. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011; 96(5):672-680. (Clone-specific: Immunocytochemistry (cytospins)) Yamashiro S, Yamakita Y, Totsukawa G, et al. Myosin phosphatase targeting subunit1 regulates mitosis by antagonizing polo-like kinase1. Dev Cell. 2008; 14(5):787-797. (Clone-specific: Immunofluorescence, Western blot)

BD Biosciences

bdbiosciences.com United States Canada Europe 877.232.8995 800.979.9408 32.53.720.550 0120.8555.90

65.6861.0633 For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be constructed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be help responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express

Asia Pacific

Latin America/Caribbean

55.11.5185.9995

written authorization of Becton, Dickinson and Company is stictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2011 BD

Japan

